These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31451965)

  • 21. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
    Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
    BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
    Livermore J; Hope W
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.
    Arsiè E; Piconi S; Iavarone M; Cozzi V; Lampertico P; Cattaneo D
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1089-1090. PubMed ID: 29666903
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
    Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
    Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease.
    Lee A; Prideaux B; Lee MH; Zimmerman M; Dolgov E; Perlin DS; Zhao Y
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30988140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isavuconazole Treatment of Invasive Fungal Sinusitis: A Post Hoc Analysis of the SECURE and VITAL Trials.
    Durand ML; Kitt TM; Song Y; Marty FM
    Clin Infect Dis; 2021 Sep; 73(6):e1380-e1383. PubMed ID: 33914864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isavuconazole: is there a need for a new antifungal?
    Cornely OA
    J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i2-i4. PubMed ID: 28355461
    [No Abstract]   [Full Text] [Related]  

  • 31. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
    Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
    Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
    Pasqualotto AC; Thiele KO; Goldani LZ
    Curr Opin Investig Drugs; 2010 Feb; 11(2):165-74. PubMed ID: 20112166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isavuconazole: A New Option for the Management of Invasive Fungal Infections.
    Pettit NN; Carver PL
    Ann Pharmacother; 2015 Jul; 49(7):825-42. PubMed ID: 25940222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.
    Miceli MH; Kauffman CA
    Clin Infect Dis; 2015 Nov; 61(10):1558-65. PubMed ID: 26179012
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and effectiveness of isavuconazole in real-life non-neutropenic patients.
    Monzó-Gallo P; Lopera C; Badía-Tejero AM; Machado M; García-Rodríguez J; Vidal-Cortés P; Merino E; Calderón J; Fortún J; Palacios-Baena ZR; Pemán J; Sanchis JR; Aguilar-Guisado M; Gudiol C; Ramos JC; Sánchez-Romero I; Martin-Davila P; López-Cortés LE; Salavert M; Ruiz-Camps I; Chumbita M; Aiello TF; Peyrony O; Puerta-Alcalde P; Soriano A; Marco F; Garcia-Vidal C
    Int J Infect Dis; 2024 Jul; 144():107070. PubMed ID: 38663477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.
    Gebremariam T; Alkhazraji S; Baldin C; Kovanda L; Wiederhold NP; Ibrahim AS
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.
    Schwartz S; Cornely OA; Hamed K; Marty FM; Maertens J; Rahav G; Herbrecht R; Heinz WJ
    Med Mycol; 2020 Jun; 58(4):417-424. PubMed ID: 31613363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review and network meta-analysis of clinical outcomes associated with isavuconazole versus relevant comparators for patients with invasive aspergillosis.
    Herbrecht R; Kuessner D; Pooley N; Posthumus J; Escrig C
    Curr Med Res Opin; 2018 Dec; 34(12):2187-2195. PubMed ID: 30022696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.